Semin intervent Radiol 2003; 20(4): 293-302
DOI: 10.1055/s-2004-828940
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Renal Radiofrequency Ablation

Brian C. Lucey, Debra A. Gervais, Peter R. Mueller
  • Division of Abdominal Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts
Further Information

Publication History

Publication Date:
20 July 2004 (online)

Preview

ABSTRACT

Radiofrequency ablation (RFA) is a technique that has been available for a considerable period of time. Although initially performed for ablating abnormal conduction pathways in the heart, the concept soon spread to include destruction of tumor tissue. This was first demonstrated with liver tumors, both hepatocellular carcinoma and metastatic disease.[1] [2] [3] [4] [5] Following the favorable early results with liver tumors, the kidney became the next focus of attention for RFA. There are many reasons that a technique such as RFA is useful in treating renal cell carcinoma (RCC) and also why the kidney is a suitable organ for successful RFA.

The incidence of RCC is rising.[6] In addition, the exponential increase in cross-sectional imaging as a first-line investigation for a myriad of indications has resulted in the earlier detection of renal tumors that are asymptomatic and would remain otherwise undetected. The natural history of RCC is extremely variable and, although some tumors are aggressive, many of these tumors grow slowly and are slow to metastasize. This presents a difficult clinical problem. Despite the relative indolence of RCC, predicting the course of any one cancer is impossible, and once detected, the clinician feels obligated to treat the disease. While this may seem entirely appropriate in most settings, it is not so clear, for example, if a nephrectomy for a 2 cm RCC is warranted in an 85-year-old patient with contralateral renal impairment. Given the morbidity and mortality associated with nephrectomy, often for small and indolent tumors, less invasive techniques have been sought for treating these tumors. This has led to the development of nephron-sparing surgery[7] [8] or partial nephrectomy, which at least preserves renal function and is less likely to result in the patient requiring dialysis following the procedure. There is, however, a substantial morbidity and mortality related to partial nephrectomy and a percutaneous technique of tumor treatment, particularly in patients who are high risk for surgical procedures, is desirable. Percutaneous RFA of renal tumors allows for localized tumor destruction and preservation of uninvolved renal parenchyma. It is the ability to treat tumor and maintain renal function that makes renal RFA such an attractive treatment option. Some patients have RCC in a solitary kidney. In both these scenarios, any renal function that is preserved may help keep the patient off dialysis.

REFERENCES